Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
COMMON STOCK · CUSIP: 05338F306
Event date: 2026-09-30
- Filing-level shares
- 2,563,226.00
- Percent of class
- 4.8%
- STATE STREET CORPORATION
Shares: 2,563,226.00 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000093751-26-000620
- Form type
- SCHEDULE 13G
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Nov 10, 2026
- Reporting period
- Sep 30, 2026
- Description
- Schedule 13G beneficial ownership